Imeglimin Add-On to Insulin Monotherapy in Japanese Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
Diabetes Obes Metab 2022 Jan 04;[EPub Ahead of Print], C Reilhac, J Dubourg, C Thang, JM Grouin, P Fouqueray, H WatadaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.